Emerging Modalities and Targets Driving Precision Oncology
The Oncology Stream at the PEGS Boston Summit 2026 will present cutting-edge advances in antibody-based therapeutics and targeted cancer modalities, bringing together leaders from academia, biotech, and pharma to drive the next wave of innovation. Across three focused conferences—Antibodies for Cancer Therapy, Emerging Targets for Oncology and Beyond, and Driving Clinical Success in Antibody-Drug Conjugates—attendees will explore the latest breakthroughs in T cell engagers, bispecifics, conditional antibodies and novel scaffolds; uncover novel tumor-associated, intracellular and “undruggable” targets with the help of AI-enabled discovery platforms; and take a deep dive into the evolving ADC landscape, including dual payloads, next generation linkers, and conjugates that integrate degraders, cytokines, and oligonucleotides. With case studies of recent clinical successes, insights into translational challenges, and showcases of innovative formats and designs, this stream offers a comprehensive view of how oncology biologics are reshaping treatment paradigms and accelerating precision medicine.
Conferences Include:
May 11-12
Antibodies for Cancer Therapy
May 12-13
Emerging Targets for Oncology and Beyond
May 14-15
Driving Clinical Success in Antibody-Drug Conjugates